Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials

European Heart Journal

Volumn 31, Issue 1, 2010, Pages 35-49

  Valgimigli, Marco ^a   Biondi Zoccai, Giuseppe ^b   Tebaldi, Matteo ^a   Van 'T Hof, Arnoud W J ^c   Campo, Gianluca ^a   Hamm, Christian ^d   Ten Berg, Jurriën ^e   Bolognese, Leonardo ^f   Saia, Francesco ^g   Danzi, Gian Battista ^h   Briguori, Carlo ⁱ   Okmen, Ertan ^j   King, Spencer B ^k   Moliterno, David J ^l   Topol, Eric J ^m  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Isala Klinieken ^*  (Netherlands)

^d KERCKHOFF HEART CENTER   (Germany)

^e ST ANTONIUS HOSPITAL   (Netherlands)

^f IRCCS POLICLINICO SAN DONATO   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ Clinica Mediterranea   (Italy)

^j DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^k Saint Joseph's Heart and Vascular Institute   (United States)

^l UNIVERSITY OF KENTUCKY   (United States)

^m SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

more..

Author keywords

Abciximab; Glycoprotein IIb IIIa inhibitors; Percutaneous coronary intervention; Systematic review; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADD ON THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CHEMOTHERAPY, ADJUVANT; HEMORRHAGE; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; TYROSINE;

EID: 73949101141     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp376     Document Type: Article

References (52)

1. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical usě Circulation 1999; 100: 437-444.
2. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353: 227-231.
3. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002;106:1470-1476.
4. Lele M, Sajid M, Wajih N, Stouffer GA. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001;104:582-587.
5. Reininger AJ, Agneskirchner J, Bode PA, Spannagl M, Wurzinger LJ. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor\-results from patients with acute myocardial infarction and healthy controls. Thromb Haemost 2000;83:217-223
6. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myo-cardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-1453.
7. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
8. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
9. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofi-ban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
10. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R. Comparison of angio-plasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTI-STRATEGY randomized trial. J Am Med Assoc 2008;299:1788-1799.
11. Higgins JPT, Green SG (eds). In: Cochrane Handbook for Systematic Reviews of Interventions. 2008. Version 501. Available from http://www.cochrane- handbookorg (last accessed on 18 May 2009).
12. Wong SS, Wilczynski NL, Haynes RB. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc 2006;94:451-455.
13. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985;312:932-936.
14. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. J Am Med Assoc 2006;295: 676-680.
15. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-542.
16. Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, King SB III. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998;32:28-34.
17. Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, Wacker C, Waller C, Kochsiek N, Meesmann M, Neyses L, Schanzenbacher P, Ertl G, Voelker W. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pre-treatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002; 40:662-668.
18. Juergens CP, White HD, Belardi JA, Macaya C, Soler-Soler J, Meyer BJ, Levy RD, Bunt T, Menten J, Herrmann HC, Adgey AA, Tarnesby G. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intra-coronary stent placement. Clin Ther 2002;24:1332-1344.
19. Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C, Vittori L. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003;42: 1348-1356.
20. Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Santopinto J, Hecquet C, Vittori L. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation 2003;108:III14-III21.
21. Okmen E, Cakmak M, Tartan Z, Cam N. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction. Heart Vessels 2003;18:117-122.
22. Ercan E, Tengiz I, Duman C, Onbasili OA, Baris N. Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction. Am Heart J 2004; 147:E1.
23. Martinez-Rios MA, Rosas M, Gonzalez H, Pena-Duque MA, Martinez-Sanchez C, Gaspar J, Garcia H, Gaxiola E, Delgado L, Carrillo J, Leyva JL, Lupi E. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocar-dial infarction. Am J Cardiol 2004;93:280-287.
24. Okmen E, Sanli A, Uyarel H, Dayi S, Tartan Z, Cam N. Effects of glycoprotein IIb/ IIIa receptor inhibition with tirofiban on minor myocardial damage in angiographi-cally successful percutaneous coronary angioplasty. Cardiology 2004;102:18-23.
25. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004;44:14-19.
26. Kim JH, Jeong MH, Rhew JY, Lim JH, Yun KH, Kim KH, Kang DK, Hong SN, Lim SY, Lee SH, Lee YS, Hong YJ, Park HW, Kim W, Ahn YK, Moon Y, Cho JG, Park JC, Kang JC. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome. Circ J 2005;69:159-164.
27. Kurowski V, Toelg R, Jain D, Richter C, Wiegand UK, Richardt G, Khattab AA. Effect of adjunctive treatment with tirofiban on troponin T elevation during stent-ing of critically stenosed aortocoronary saphenous vein grafts. Am J Cardiol 2005; 96:681-684.
28. Ozkan M, Sag C, Yokusoglu M, Uzun M, Baysan O, Erinc K, Isik E. The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes. Tohoku J Exp Med 2005; 206:7-13.
29. Rasoul S, Ottervanger JP, de Boer MJ, Miedema K, Hoorntje JC, Gosselink M, Zijlstra F, Suryapranata H, Dambrink JH, van 't Hof AW. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial. Eur Heart J 2006;27:1401-1407.
30. Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, Hao GZ, Li SQ, Jiang YF, Geng W. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J 2008;121:522-527.
31. Ivandic BT, Kurz K, Keck F, Staritz P, Lehrke S, Katus HA, Giannitsis E. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes. Thromb Haemost 2008;100:648-654.
32. Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis 2008;19:271-277.
33. Van 't Hof AW, ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008;372: 537-546.
34. Briguori C. NAPLES: a prospective, randomized trial comparison of bivalirudin and unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. 2008; Presented at TCT; Available at http://www.tctmd.com/txshow.aspx?tid=2434&id= 70954&trid=2380.
35. Valgimigli M. Main results of the tailoring treatment with tirofiban in patients showing resistance to aspirin or resistance to clopidogrel study (3T/2R). 2008; Presented at ESC; Available at http://resources.escardio.org/ Webcast/ESC% 2D2008/3210/.
36. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, Tarducci R, Cosmi F, Baldassarre S, Burali A. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006;47: 522-528.
37. Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol 2004;94:35-39.
38. Marzocchi A, Manari A, Piovaccari G, Marrozzini C, Marra S, Magnavacchi P, Sangiorgio P, Marinucci L, Taglieri N, Gordini G, Binetti N, Guiducci V, Franco N, Reggiani ML, Saia F. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 2008;29:2972-2980.
39. Mukherjee D, Topol EJ, Bertrand ME, Kristensen SD, Herrmann HC, Neumann FJ, Yakubov SJ, Bassand JP, McClure RR, Stone GW, Ardissino D, Moliterno DJ. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 2005;26:2524-2528.
40. Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplate-let effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001;37:1323-1328.
41. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. J Am Med Assoc 2005;293: 2109-2117.
42. Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Zijlstra F, van 't Hof AW. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myo-cardial infarction. J Am Coll Cardiol 2004;44:1187-1193.
43. Moliterno DJ. Tirofiban Evaluation of Novel Dosing vs. Abciximab with Clopido-grel and Inhibition of Thrombin Study. The TENACITY. 2005; Presented at TCT.
44. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. Abciximab as adjunctive therapy to reper-fusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Am Med Assoc 2005;293:1759-1765.
45. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. J Am Med Assoc 2006;295:1531-1538.
46. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopi-dogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-1159.
47. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Sub-optimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-650.
48. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, Aggarwal A, Kabbani SS, DiBattiste PM. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003;91:334-336.
49. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Bonizzoni E, Topol EJ, Chiariello M. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revasculariza-tion for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol 2006;47:685-686.
50. Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am J Cardiol 2006;97:489-493.
51. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203-2206.
52. McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999;99:2892-2900.